Urogen Pharma(GB:0XOD)
$25.99+0.67 (+2.65%)
GB:0XOD
Urogen Pharma ownership
$25.99
At close:+0.67 (+2.65%)
Urogen Pharma (0XOD) Ownership - Who Owns Urogen Pharma?
1 Followers
Urogen Pharma (0XOD) Ownership Overview
- 1.77% Insiders
- 5.60% Mutual Funds
- 7.78% Other Institutional Investors
- 7.48% ETFs
- 77.36% Public Companies and Individual Investors
The ownership structure of Urogen Pharma (GB:0XOD) stock is a mix of institutional, retail, and individual investors. Approximately 20.87% of the company’s stock is owned by Institutional Investors, 1.77% is owned by Insiders, and 77.36% is owned by Public Companies and Individual Investors.
The ownership structure of Urogen Pharma (GB:0XOD) stock is a mix of institutional, retail, and individual investors. Approximately 20.87% of the company’s stock is owned by Institutional Investors, 1.77% is owned by Insiders, and 77.36% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Aug 23, 2026 | Mark Schoenberg | $2,854,853 | |
| Feb 03, 2026 | Mark Schoenberg | $145,174 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Aisling Capital Management Lp | $2,529,360 | |
| Dec 31, 2025 | Ark Investment Management Llc | $2,845,155 | |
| Dec 31, 2025 | Woodline Partners Lp | $11,727,002 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 3,201,461 | Institution | 6.53% | 83,205,971 |
| Ishares | 2,268,425 | Institution | 4.62% | 58,956,366 |
| American Century Mutual Funds, Inc. | 874,981 | Institution | 1.78% | 22,740,756 |
| Fidelity Salem Street Trust | 507,789 | Institution | 1.04% | 13,197,436 |
| Michael Rockefeller | 500,726 | Institution | 1.02% | 13,013,869 |
| Vanguard | 470,752 | Institution | 0.96% | 12,234,844 |
| Vanguard Scottsdale Funds | 420,842 | Institution | 0.86% | 10,937,684 |
| Arie Belldegrun | 408,693 | Insider | 0.83% | 10,621,931 |
| Elizabeth A. Barrett | 326,691 | Insider | 0.67% | 8,490,699 |
| Fidelity | 254,384 | Institution | 0.52% | 6,611,440 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| American Century Mutual Funds, Inc. | 874,981 | Institution | 1.78% | 22,740,756 |
| Fidelity Salem Street Trust | 507,789 | Institution | 1.04% | 13,197,436 |
| Vanguard Scottsdale Funds | 420,842 | Institution | 0.86% | 10,937,684 |
| Tiaa-cref Funds | 158,899 | Institution | 0.32% | 4,129,785 |
| Schwab Capital Trust | 126,848 | Institution | 0.26% | 3,296,780 |
| Vanguard World Fund | 118,428 | Institution | 0.24% | 3,077,944 |
| Valic Co I | 113,987 | Institution | 0.23% | 2,962,522 |
| Clearwater Investment Trust | 67,706 | Institution | 0.14% | 1,759,679 |
| Federated Hermes Mdt Series | 60,521 | Institution | 0.12% | 1,572,941 |
| Russell Investment Co | 46,964 | Institution | 0.10% | 1,220,594 |
FAQ
Who Owns Urogen Pharma (GB:0XOD)?
According to the latest TipRanks data, approximately 20.87% of the company's stock is held by institutional investors, 1.77% is held by insiders, and 77.36% is held by public companies and individual investors.
What percentage of Urogen Pharma (GB:0XOD) stock is held by institutional investors?
According to the latest TipRanks data, approximately 20.87% of Urogen Pharma (GB:0XOD) stock is held by institutional investors: 5.60% by mutual funds, 7.48% by ETFs and 7.78% by other institutional investors.
What percentage of Urogen Pharma (GB:0XOD) stock is held by retail investors?
According to the latest TipRanks data, approximately 77.36% of Urogen Pharma (GB:0XOD) stock is held by public companies and individual investors.
Who owns the most shares of Urogen Pharma (GB:0XOD)?
BlackRock, Inc. owns the most shares of Urogen Pharma (GB:0XOD).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
